NLS Pharma article

Norwegian microbiome diagnostics company Genetic Analysis is presenting results today at UEG Week 2026 in Barcelona on GA-map IBD Precision Dx, a test designed to identify, at diagnosis, which ulcerative colitis patients are at risk of an aggressive disease course.

For bladder cancer patients, the hardest part of treatment is often not knowing whether it will work. At Karolinska Institutet and SciLifeLab, researchers are developing tools that read a tumor's own molecular signals to predict who will benefit from novel systemic therapies – before treatment even begins.

The World Health Organization (WHO) has identified SynAct Pharma's resomelagon as one of six dengue drug candidates with evidence supporting further clinical development, according to a review published in The Lancet Microbe.

A Swedish healthcare delegation traveled to Kyiv on September 2–4 to strengthen cooperation on rebuilding Ukraine's healthcare system, timed to one of the most difficult periods for the city in months.

The ongoing struggle in the Nordic countries to keep prescription drug prices affordable without shutting out innovative, more expensive therapies continues to frustrate pharmaceutical companies as the introduction of new drugs to the region slows.

In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.